A5017209583- Lung Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Management of metastatic bone disease
- Medical Imaging Techniques and Applications
- Brain Metastases and Treatment
- Radiation Therapy and Dosimetry
- Head and Neck Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Cancer Genomics and Diagnostics
- Tracheal and airway disorders
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Orthopedic Surgery and Rehabilitation
- Orthopaedic implants and arthroplasty
- Foot and Ankle Surgery
- Diagnosis and Treatment of Venous Diseases
- BRCA gene mutations in cancer
- Orthopedic Infections and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Alfred Health
2013-2024
Southmead Hospital
2024
North Bristol NHS Trust
2024
Monash University
2016-2023
The Alfred Hospital
2015-2020
Avon Medical Centre
2018
The William Buckland Foundation
2013-2015
Vrije Universiteit Amsterdam
2013
Amsterdam UMC Location Vrije Universiteit Amsterdam
2012-2013
Peter MacCallum Cancer Centre
2011-2013
The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites can be ablated. However, randomized data test this are lacking.We enrolled controlled primary malignancy and 1-5 metastatic lesions, amenable to stereotactic ablative radiotherapy (SABR). We stratified by the (1-3 v 4-5) in 1:2 ratio between palliative standard-of-care (SOC) treatments (arm 1) SOC plus SABR 2). used phase II screening...
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control primary tumors or metastases. A recent randomized phase II trial evaluated in group small burden disease (mostly 1–3 metastatic lesions), found that was associated benefits progression-free survival overall survival. The goal this III is to assess the impact...
Abstract Background A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with small burden oligometastatic disease (mostly 1–3 metastatic lesions), and found that SABR was associated significant improvement progression-free survival trend to an overall benefit, supporting progression III trials. Methods Two hundred ninety-seven will be 1:2 ratio between the control arm (consisting standard care [SOC] palliative-intent treatments), SOC...
Abstract Purpose The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites can be ablated. However, randomized data testing this are lacking. Methods We enrolled controlled primary malignancy and 1-5 metastatic lesions, amenable to stereotactic ablative radiotherapy (SABR). stratified by the (1-3 vs. 4-5) in 1:2 ratio between palliative standard care (SOC) treatments (Arm 1) SOC plus SABR 2)....
Second primary non-small cell lung cancer (SPLC) is a significant cause of death amongst survivors. As subsequent surgery seldom feasible post-pneumonectomy, we studied the long-term clinical outcomes achieved with curative radiotherapy using modern delivery techniques.Retrospective review an institutional database between 2003-2011 identified 27 patients who had received for SPLC arising post-pneumonectomy. Treatments included; stereotactic ablative (SABR, n=20, dose 54-60 Gy in 3-8...
Data about factors driving accrual to radiation oncology trials are limited. In oncology, 30%-40% of considered unsuccessful, many because poor accrual. The goal the present study was inform design future by evaluating effects institutional, clinician, and patient on rates a randomized trial.Investigators participating in sabr-comet (NCT01446744), phase ii trial open Canada, Europe, Australia that is role stereotactic ablative radiotherapy (sabr) oligometastatic disease, were invited...
Abstract Background Radiotherapy delivery regimens can vary between a single fraction (SF) and multiple fractions (MF) given daily for up to several weeks depending on the location of cancer or metastases. With limited evidence comparing fractionation oligometastases, there is support explore toxicity levels nearby organs at risk as primary outcome while using SF MF stereotactic ablative radiotherapy (SABR) well differences in patient-reported quality life experience. Methods This study will...
Backgound. Stereotactic radiotherapy for central lung tumors has a narrower therapeutic index than that peripheral tumors. Tumor tracking strategies have been proposed to reduce treatment volumes and toxicity, however they need consider uncertainties in tumor size shape change throughout respiration ensure optimal local control. We quantified these explored account them. Material methods. Ten patients with tumors, PTV > 100 cm3, motion 5 mm 10-phase 4DCT without significant artifact the...
Intensity modulated radiotherapy (IMRT) is routinely utilized in the treatment of locally advanced non-small cell lung cancer (NSCLC). RTOG 0617 found that overall survival was impacted by increased low (5 Gy) and intermediate (30 cardiac doses. We evaluated impact esophageal-sparing IMRT on doses with without heart considered planning process predicted toxicity compared to 3D-conventional (3DCRT).Ten consecutive patients N2 Stage III NSCLC treated 60 Gy 30 fractions, between February 2012...